tradingkey.logo
tradingkey.logo
Search

Embecta Corp

EMBC
Add to Watchlist
5.620USD
+0.040+0.72%
Close 09-24 16:00(ET)
333.43MMarket Cap
2.94P/E TTM

About Embecta Corp Company

Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.

Embecta Corp Profile

Ticker SymbolEMBC
Company nameEmbecta Corp
IPO dateMar 21, 2022
CEOKurdikar (Devdatt)
Number of employees1850
Security typeOrdinary Share
Fiscal year-endMar 21
Address300 Kimball Drive
CityPARSIPPANY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07054
Phone18624010000
Websitehttps://www.embecta.com/
Ticker SymbolEMBC
IPO dateMar 21, 2022
CEOKurdikar (Devdatt)

Company Executives of Embecta Corp

Name
Name/Position
Position
Shareholding
Change
Mr. Devdatt (Dev) Kurdikar
Mr. Devdatt (Dev) Kurdikar
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
321.24K
+9.34%
Mr. Devdatt (Dev) Kurdikar
Mr. Devdatt (Dev) Kurdikar
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
321.24K
+9.34%
Mr. Jacob (Jake) Elguicze
Mr. Jacob (Jake) Elguicze
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
134.14K
+14.91%
Mr. Jacob (Jake) Elguicze
Mr. Jacob (Jake) Elguicze
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
134.14K
+14.91%
Mr. Jeffrey Z. (Jeff) Mann
Mr. Jeffrey Z. (Jeff) Mann
Senior Vice President, General Counsel, Product Development
Senior Vice President, General Counsel, Product Development
115.43K
+17.33%
Mr. Jeffrey Z. (Jeff) Mann
Mr. Jeffrey Z. (Jeff) Mann
Senior Vice President, General Counsel, Product Development
Senior Vice President, General Counsel, Product Development
115.43K
+17.33%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
94.70K
+47.52%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
94.70K
+47.52%
Mr. Christopher R. (Chris) Reidy
Mr. Christopher R. (Chris) Reidy
Independent Director
Independent Director
55.24K
+41.35%
Mr. Christopher R. (Chris) Reidy
Mr. Christopher R. (Chris) Reidy
Independent Director
Independent Director
55.24K
+41.35%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Devdatt (Dev) Kurdikar
Mr. Devdatt (Dev) Kurdikar
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
321.24K
+9.34%
Mr. Devdatt (Dev) Kurdikar
Mr. Devdatt (Dev) Kurdikar
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
321.24K
+9.34%
Mr. Jacob (Jake) Elguicze
Mr. Jacob (Jake) Elguicze
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
134.14K
+14.91%
Mr. Jacob (Jake) Elguicze
Mr. Jacob (Jake) Elguicze
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
134.14K
+14.91%
Mr. Jeffrey Z. (Jeff) Mann
Mr. Jeffrey Z. (Jeff) Mann
Senior Vice President, General Counsel, Product Development
Senior Vice President, General Counsel, Product Development
115.43K
+17.33%
Mr. Jeffrey Z. (Jeff) Mann
Mr. Jeffrey Z. (Jeff) Mann
Senior Vice President, General Counsel, Product Development
Senior Vice President, General Counsel, Product Development
115.43K
+17.33%

FAQs

Who are the top five shareholders of Embecta Corp?

The top five shareholders of Embecta Corp are: Mr. Devdatt (Dev) Kurdikar

How many institutions hold shares of Embecta Corp (EMBC)?

As of 2026Q1, 791 institutions hold shares of Embecta Corp, with a combined market value of approximately 59.40M, accounting for 100.13% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -4635325.00.

What is the biggest source of revenue for Embecta Corp?

In 2026Q1, the Pen Needles business generated the highest revenue for Embecta Corp, amounting to 177.50M and accounting for 65.33% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.